Percutaneous Device Closure Plus Antiplatelet Therapy
For patients under 60 years old with cryptogenic stroke and PFO, percutaneous device closure followed by antiplatelet therapy is strongly recommended over antiplatelet therapy alone, with high-quality evidence showing substantial reduction in recurrent stroke risk. 1
Treatment Algorithm Based on Patient Eligibility
First-Line Approach: PFO Closure + Antiplatelet Therapy
When anticoagulation is contraindicated or declined:
- Strong recommendation for PFO closure plus antiplatelet therapy versus antiplatelet therapy alone 1
- This provides an 87 fewer recurrent strokes per 1000 patients over 5 years (high certainty evidence) 2
- Procedure takes under 2 hours, hospital stay typically one day, full recovery within weeks 1
When all options are acceptable:
- Weak recommendation for PFO closure plus antiplatelet therapy over anticoagulation 1
- PFO closure probably decreases major bleeding compared to anticoagulation 1
- However, closure increases risk of persistent atrial fibrillation (18 more per 1000 patients) and device-related adverse events (36 more per 1000 patients) 1, 2
Alternative: Anticoagulation Alone
When PFO closure is contraindicated or declined:
- Weak recommendation for anticoagulation over antiplatelet therapy 1
- May reduce recurrent stroke by 71 per 1000 patients over 5 years (low certainty) 2
- Increases major bleeding risk by 12 per 1000 patients (moderate certainty) 2
Critical Patient Selection Criteria
Age is the most important factor:
- Guidelines apply specifically to patients under 60 years old 1
- In older patients, fewer cryptogenic strokes are caused by paradoxical emboli, so benefits of closure are smaller and harms greater 1
- Recent data suggests closure may be safe in select patients ≥60 years with low comorbidity, but this remains outside current guideline recommendations 3
Essential diagnostic workup before closure:
- Extensive evaluation to exclude other stroke etiologies (prolonged rhythm monitoring for atrial fibrillation, transesophageal echocardiography, carotid imaging) 1
- Assessment of high-risk PFO features (atrial septal aneurysm, large shunt) 4, 5
- Risk of Paradoxical Embolism (RoPE) score >8 with clinical risk factors favors closure 1, 5
Key Practical Considerations
Advantages of percutaneous closure:
- Substantial stroke reduction benefit that outweighs procedural risks for most patients under 60 1
- Avoids long-term bleeding risk associated with anticoagulation 1
- High success rate approaching 100% with modern devices 5
Common pitfalls to avoid:
- Do not offer closure to unselected patients without thorough cryptogenic stroke workup 1
- Atrial fibrillation after closure is mostly transient (first 3 months) and does not typically require anticoagulation 5
- Device-related adverse events occur but are generally manageable 1
When medical therapy is chosen:
- Anticoagulation may be preferred over antiplatelet therapy for possible stroke reduction, though evidence is lower quality 1, 2
- Vitamin K antagonists and NOACs show similar efficacy, though NOACs may have slightly higher bleeding risk 6
- Antiplatelet therapy alone is considered the least effective option for secondary prevention 6
Evidence Quality Note
The 2018 BMJ guideline [1-1] represents the most recent and comprehensive evidence synthesis, incorporating network meta-analysis of randomized trials with GRADE methodology. This supersedes the 2009 advisory 7 which called for trial completion—those trials have now been completed and analyzed, establishing clear benefit for closure in appropriately selected patients.
The multidisciplinary heart-brain team approach is essential for borderline cases to determine PFO-stroke causality and optimize treatment selection 8, 5.